Jefferies Financial Group Inc. Buys New Shares in Omada Health, Inc. $OMDA

Jefferies Financial Group Inc. acquired a new stake in shares of Omada Health, Inc. (NASDAQ:OMDA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,073,991 shares of the company’s stock, valued at approximately $16,948,000. Jefferies Financial Group Inc. owned about 1.85% of Omada Health at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Strs Ohio bought a new position in shares of Omada Health during the third quarter valued at about $38,000. Raymond James Financial Inc. bought a new position in shares of Omada Health during the second quarter valued at about $32,000. TD Waterhouse Canada Inc. bought a new position in shares of Omada Health during the fourth quarter valued at about $32,000. Rakuten Investment Management Inc. bought a new position in shares of Omada Health during the third quarter valued at about $49,000. Finally, Inlight Wealth Management LLC bought a new position in shares of Omada Health during the fourth quarter valued at about $45,000.

Omada Health Price Performance

NASDAQ OMDA opened at $16.51 on Monday. The stock has a market capitalization of $981.52 million and a PE ratio of -61.15. Omada Health, Inc. has a 1 year low of $10.28 and a 1 year high of $28.40. The business’s 50-day moving average is $14.14 and its 200 day moving average is $15.12.

Omada Health (NASDAQ:OMDA) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $78.05 million for the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. As a group, equities research analysts anticipate that Omada Health, Inc. will post -0.04 earnings per share for the current year.

Insider Buying and Selling

In related news, President Wei-Li Shao sold 2,829 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $12.71, for a total value of $35,956.59. Following the sale, the president directly owned 328,850 shares of the company’s stock, valued at $4,179,683.50. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Steven L. Cook sold 1,884 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $13.94, for a total transaction of $26,262.96. Following the completion of the sale, the chief financial officer owned 200,512 shares of the company’s stock, valued at $2,795,137.28. This trade represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 8,776 shares of company stock valued at $120,483 over the last ninety days. 6.38% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on OMDA shares. Morgan Stanley reduced their price objective on Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, March 6th. Citigroup reaffirmed an “outperform” rating on shares of Omada Health in a research note on Friday, May 8th. Barclays raised their price objective on Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Canaccord Genuity Group set a $24.00 target price on Omada Health in a research note on Friday, May 8th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a research note on Friday, May 8th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Omada Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.91.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.